Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Source: Forbes.com Healthcare News - July 28, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news